Trial Profile
A PHASE I STUDY OF THE COMBINATION OF CAI AND PACLITAXEL IN ADULT PATIENTS WITH REFRACTORY CANCERS OR LYMPHOMA.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs L 651582 (Primary) ; Paclitaxel
- Indications Breast cancer; Lymphoma; Ovarian cancer
- Focus Adverse reactions
- 14 Mar 2012 Actual end date (Jul 2006) added as reported by ClinicalTrials.gov.
- 26 Apr 2007 Status changed to completed
- 04 Sep 2005 New trial record.